Status:
COMPLETED
The Relation Between Plasma Irisin Level and Endothelial Dysfunction in Type 2 Diabetes
Lead Sponsor:
Wuhan General Hospital of Guangzhou Military Command
Conditions:
Irisin
Endothelial Dysfunction
Eligibility:
All Genders
40-70 years
Brief Summary
Irisin is a signaling protein that is released into the blood from skeletal muscle after proteolysis of the membrane protein FNDC5 . FNDC5, encoded by the Fndc5 gene. Irisin activity on subcutaneous w...
Eligibility Criteria
Inclusion
- newly diagnosed type 2 diabetic patients
- aged 40～70 years
Exclusion
- Patients with hypertension and those with micro- and macroangiopathy, including nephropathy \[urinary albumin excretion rate (UAER) \> 20 μg/min\], retinopathy (at least one microaneurysm or hemorrhage or exudates in either eye), neuropathy (pain in extremities, paresthesias, and absent tendon reflexes and/or absent vibration sense), coronary artery disease (myocardial infarction, ischemia electrocardiogram changes, and angina), cerebrovascular disease (transient ischemic attack or stroke), and peripheral vascular disease (the abolition of one or more peripheral arterial pulse and/or intermittent claudication and/or a past history of revascularization of the lower limbs) were excluded from the study.
Key Trial Info
Start Date :
July 1 2013
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2013
Estimated Enrollment :
200 Patients enrolled
Trial Details
Trial ID
NCT01877603
Start Date
July 1 2013
End Date
December 1 2013
Last Update
June 16 2015
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Wuhan General Hospital
Wuhan, Hubei, China, 430070